Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromuscular Blocks Clear all
Completed No phase listed Observational

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

NCT03585348
View directory record Official record
Conditions
Neuromuscular Blockade, Residual Curarisation, Postoperative, Surgery Under General Anaesthesia
Interventions
Neuromuscular blocking agents
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
265,537 participants
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

NCT02728726
View directory record Official record
Conditions
General Surgery
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 21, 2026, 4:23 AM EDT
Completed No phase listed Observational

Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery

NCT02285829
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Rocuronium Bromide, Cisatracurium Besylate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 21, 2026, 4:23 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Comparison of Sugammadex and Neostigmine During PACU Stay

NCT04096144
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neuromuscular Blocking Agents
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 21, 2026, 4:23 AM EDT
Completed No phase listed Observational

Provider Perceptions of Neuromuscular Blockade in ARDS

NCT03179709
View directory record Official record
Conditions
Neuromuscular Blockade, Acute Respiratory Distress Syndrome
Interventions
Interview
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

Effect of Stellate Ganglion Block on ME/CFS

NCT05664711
View directory record Official record
Conditions
Encephalomyelitis, Myalgic, Chronic Fatigue Syndrome, Chronic Fatigue Disorder, Chronic Fatigue and Immune Dysfunction Syndrome, Myalgic Encephalomyelitis, Postviral Fatigue Syndrome, Systemic Exertion Intolerance Disease, Infectious Mononucleosis-Like Syndrome, Chronic, Chronic Fatigue-Fibromyalgia Syndrome
Interventions
Bupivacaine Injection
Drug
Lead sponsor
Neuroversion, Inc.
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting

NCT04352140
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Tetragraph, ToFscan
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 21, 2026, 4:23 AM EDT
Terminated No phase listed Observational

Clinical Evaluation of a Novel Neuromuscular Blockade Monitoring System

NCT04406740
View directory record Official record
Conditions
Anesthesia
Interventions
TwitchView EMG Unit, Novel QTOF Device
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

NCT03168308
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine w/ Glycopyrrolate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

NCT00001520
View directory record Official record
Conditions
Paralysis
Interventions
neostigmine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fade Upon TOF Stimulation Induced by Succinylcholine

NCT02425449
View directory record Official record
Conditions
Muscle Relaxants
Interventions
Succinylcholine
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 21, 2026, 4:23 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

NCT07203287
View directory record Official record
Conditions
Post Operative Pulmonary Complications, Neuromuscular Blockade, General Anesthesia
Interventions
Rocuronium, Cisatracurium, Sugammadex, Neostigmine
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

NCT03923556
View directory record Official record
Conditions
Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex

NCT03543826
View directory record Official record
Conditions
Muscle Weakness
Interventions
Protocol for rocuronium neuromuscular block
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 21, 2026, 4:23 AM EDT
Recruiting Not applicable Interventional

NMT EasyFit Sensor and Cable

NCT07394140
View directory record Official record
Conditions
Neuromuscular Blockade Monitoring, NMT
Interventions
Collection of NMT Technology
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)

NCT01441960
View directory record Official record
Conditions
Neuromuscular Blockade, ECT
Interventions
Succinylcholine, Rocuronium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 21, 2026, 4:23 AM EDT
Recruiting No phase listed Observational

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619
View directory record Official record
Conditions
Melanoma
Interventions
Single agent, adjuvant anti-PD1 therapy
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 21, 2026, 4:23 AM EDT
Not listed No phase listed Observational

Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS

NCT03038906
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Neuromyopathies
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 21, 2026, 4:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electromyographic Assessment of the TetraGraph in Normal Volunteers

NCT02912039
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
TetraGraph, TOF Watch
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 21, 2026, 4:23 AM EDT
Completed No phase listed Observational Results available

The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade

NCT01545193
View directory record Official record
Conditions
Residual Neuromuscular Blockade in Elderly Patients
Interventions
Age and incidence of residual neuromuscular blockade
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 21, 2026, 4:23 AM EDT
Recruiting Phase 3 Interventional

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

NCT06136585
View directory record Official record
Conditions
Neuromuscular Blocks
Interventions
2 mg/kg sugammadex, 0.07 mg/kg neostigmine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex Titration in Cardiac Surgery Patients

NCT05246397
View directory record Official record
Conditions
Coronary Artery Disease, Valvular Heart Disease, Aorta Disease, Heart Failure
Interventions
Sugammadex administration
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 21, 2026, 4:23 AM EDT